Envista Holdings Corporation delivered first-quarter 2025 results in line with expectations, building on momentum from the second half of 2024. The company reported sales of $617 million, a net income of $18 million, and maintained its 2025 guidance.
Sales reached $617 million, with core sales increasing 0.2% over the first quarter of 2024.
Net income was $18 million, and adjusted EBITDA margin was 12.8%, consistent with expectations.
Positive growth was observed in Equipment & Consumables, Nobel Biocare, and Spark clear aligners, offsetting softness in Diagnostics and Ortho in China.
The company repurchased 1.1 million shares for approximately $19 million during the quarter, with $231 million remaining in repurchase capacity.
Envista is maintaining its full-year 2025 guidance, expecting core sales growth of 1% to 3%, adjusted EBITDA margins of approximately 14%, and adjusted earnings per share ranging between $0.95 and $1.05.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance